Evidence map›Paper›PMID 30007927›Full record

ArticleBMJ open2018

Smartphone application for preventing depression: study protocol for a workplace randomised controlled trial.

Mark Deady, David A Johnston, Nick Glozier, David Milne, Isabella Choi, Andrew Mackinnon, Arnstein Mykletun, Rafael A Calvo, Aimee Gayed, Richard Bryant and 2 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. A Pilot Evaluation of a Smartphone Application for Workplace Depression.International journal of environmental research and public health · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mark DeadyBlack Dog Institute, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
David A JohnstonBlack Dog Institute, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Nick GlozierBrain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
David MilneSchool of Electrical and Information Engineering, University of Sydney, Sydney, New South Wales, Australia.
Isabella ChoiBrain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
Andrew MackinnonBlack Dog Institute, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Arnstein MykletunNorwegian Institute of Public Health, Oslo, Norway.
Rafael A CalvoSchool of Electrical and Information Engineering, University of Sydney, Sydney, New South Wales, Australia.
Aimee GayedSchool of Psychiatry, UNSW, Sydney, NSW, Australia.
Richard BryantSchool of Psychology, UNSW, Sydney, NSW, Australia.
Helen ChristensenBlack Dog Institute, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Samuel B HarveyBlack Dog Institute, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDepression is the leading cause of life years lost due to disability. Appropriate prevention has the potential to reduce the incidence of new cases of depression, however, traditional prevention approaches face significant scalability issues. Prevention programmes delivered by via smartphone applications provide a potential solution. The workplace is an ideal setting to roll out this form of intervention, particularly among industries that are unlikely to access traditional health initiatives and whose workplace characteristics create accessibility and portability issues. The study aims to evaluate the effectiveness of a smartphone application designed to prevent depression and improve well-being. The effectiveness of the app as a universal, selective and indicated prevention tool will also be evaluated. METHODS AND ANALYSIS: A multicentre randomised controlled trial, to determine the effectiveness of the intervention compared with an active mood monitoring control in reducing depressive symptoms (primary outcome) and the prevalence of depression at 3 months, with secondary outcomes assessing well-being and work performance. Employees from a range of industries will be invited to participate. Participants with likely current depression at baseline will be excluded. Following baseline assessment, participants, blinded to their allocation, will be randomised to receive one of two versions of the application: headgear (a 30-day mental health intervention) or a control application (mood monitoring for 30 days). Both versions of the app contain a risk calculator to provide a measure of future risk. Analyses will be conducted within an intention-to-treat framework using mixed modelling, with additional analyses conducted to compare the moderating effect of baseline risk level and depression symptom severity on the intervention's effectiveness. ETHICS AND DISSEMINATION: The current trial has received ethics approval from the University of New South Wales Human Research Ethics Committee (HC17021). Study results will be disseminated through peer-reviewed journals and conferences. TRIAL REGISTRATION NUMBER: ACTRN12617000548336; Results.

Indexed as

Mobile ApplicationsSmartphoneCognitive Behavioral TherapyDepressionDepressive DisorderFemaleHumansMaleMulticenter Studies as TopicRandomized Controlled Trials as TopicTelemedicineWorkplacedepressionmhealthpreventionworkplace

Identifiers

PMID30007927
PMCPMC6089262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.